REFRACTORY MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo for tough blood cancer hits roadblock
Disease control TerminatedThis study looked at combining two drugs, venetoclax and azacitidine, to treat people with a serious type of bone marrow cancer called high-risk myelodysplastic syndrome (MDS). The goal was to find the safest dose and see if the combination could shrink or control the cancer. The…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:06 UTC
-
New drug cocktail targets tough leukemia in patients with RUNX1 mutation
Disease control TerminatedThis study tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had returned or not responded to treatment. All participants had a specific genetic change called RUNX1. The goal was to…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Experimental combo for tough leukemia shows early promise but trial stopped short
Disease control TerminatedThis early-phase study tested two chemotherapy drugs, pevonedistat and belinostat, together in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior therapy. The main goal was to find the safest dose and check for side effects.…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC